“Global Antibacterial Drugs market set to grow to $48bn by 2024” says new Visiongain report

26 April 2019
Pharma

Visiongain has launched a new pharma report Global Antibacterial Drugs Market Report : Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others.

The demand for antibacterial drugs will continue as bacterial infections are among the most common diseases worldwide. However, strong efforts to restrict antibiotic prescribing in developed and emerging markets will not only reduce bacterial resistance but will also restrain growth. The development of novel therapies, on the other hand, will be driven by increased government investment and funding from other public bodies.

The lead analyst of the report commented "As with other sectors of the pharmaceutical industry, future antibacterial drug development will be driven by innovation from small bio pharmaceutical companies, Visiongain believes.

Many of the most novel products in the development pipeline have come from small companies targeting new treatment pathways or mechanisms of action. Increased demand and funding from governments for new antibacterial drugs will benefit these small companies over the coming 10 years."

Leading companies featured in the report include Adenium Biotech ApS, Allecra Therapeutics GmbH, AstraZeneca, Bayer, BioVersys AG, Eli Lilly. GlaxoSmithKline (GSK), Merck & Co., Novartis, Pfizer and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever